ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,868.55
-0.22%
Dow Jones
42,392.27
-0.36%
US Dollar vs MXN
20.58295
-0.12%
Brent Oil
75.815
-0.05%
Bitcoin
96,246.69
-0.67%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. XOMA Royalty Corporation (XOMAP) Cotización

XOMA Royalty Corporation

XOMA Royalty Corporation (XOMAP)

NASDAQ
25.88
0.00
(0.00%)
Cerrado 03 Enero 3:00PM
Delayed by 15 minutes
25.88
0.00
(0.00%)
Fuera de horario: 3:02PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
25.88
Postura de Compra
25.19
Postura de Venta
29.21
Volume Operado de la Acción
548
25.88 Rango del Día 25.88
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
304.937M
Precio Anterior
25.88
Precio de Apertura
25.88
Hora
1
@
25.88
Última hora de negociación
Volumen financiero
US$ 14,182
Precio Promedio Ponderado
25.88
Volumen promedio (3 m)
-
Acciones en circulación
11,782,723
Rendimiento del Dividendo
8.33%
Ratio Precio/Utilidad
-7.51
Beneficio por acción (BPA)
-3.47
turnover
4.76M
Beneficio neto
-40.83M

Acerca de XOMA Royalty Corporation

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.xoma.com
Sede
Wilmington, Delaware, USA
Fundado
-
XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMAP. The last closing price for XOMA Royalty was US$25.88. Over the last year, XOMA Royalty shares have traded in a share price range of US$ 0.00 to US$ 0.00.

XOMA Royalty currently has 11,782,723 shares in issue. The market capitalisation of XOMA Royalty is US$304.94 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -7.51.

XOMAP Últimas noticias

Más noticias

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of...

19 Diciembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

02 Diciembre 2024
Edgar (US Regulatory)

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and...

02 Diciembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

13 Noviembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

13 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Noviembre 2024
Edgar (US Regulatory)

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s...

07 Noviembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

22 Octubre 2024
Edgar (US Regulatory)

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating...

22 Octubre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000PR
40000000PR
120000000PR
260000000PR
520000000PR
1560000000PR
2600000000PR

XOMAP - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de XOMA Royalty?
El precio actual de las acciones de XOMA Royalty es US$ 25.88
¿Cuántas acciones de XOMA Royalty están en circulación?
XOMA Royalty tiene 11,782,723 acciones en circulación
¿Cuál es la capitalización de mercado de XOMA Royalty?
La capitalización de mercado de XOMA Royalty es USD 304.94M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de XOMA Royalty?
XOMA Royalty ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de XOMA Royalty?
El ratio precio/beneficio de XOMA Royalty es -7.51
¿Cuál es el ratio de efectivo a ventas de XOMA Royalty?
El ratio de efectivo a ventas de XOMA Royalty es 64.41
¿Cuál es la moneda de reporte de XOMA Royalty?
XOMA Royalty presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de XOMA Royalty?
El último ingresos anual de XOMA Royalty es USD 4.76M
¿Cuál es el último beneficio anual de XOMA Royalty?
El último beneficio anual de XOMA Royalty es USD -40.83M
¿Cuál es la dirección registrada de XOMA Royalty?
La dirección registrada de XOMA Royalty es CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de XOMA Royalty?
La dirección del sitio web de XOMA Royalty es www.xoma.com
¿En qué sector industrial opera XOMA Royalty?
XOMA Royalty opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ONCBeiGene Ltd
 184.21
(731.65%)
129.32k
RAINRain Enhancement Technologies Holdco Inc
 6.75
(457.85%)
212.43k
NITON2OFF Inc
US$ 1.07
(331.45%)
603.55M
CTCXCarmell Corporation
US$ 0.6991
(150.48%)
309.04M
TXMDTherapeuticsMD Inc
US$ 1.58
(83.72%)
7.4M
NMRANeumora Therapeutics Inc
US$ 1.965
(-81.46%)
44.29M
THCHTH International Limited
US$ 0.71
(-80.00%)
46.39k
MARXMars Acquisition Corporation
US$ 2.47
(-73.58%)
1.19M
SISIShineco Inc
US$ 2.07
(-54.30%)
1.73M
MARXUMars Acquisition Corporation
US$ 6.23
(-40.10%)
66.1k
NITON2OFF Inc
US$ 1.07
(331.45%)
603.87M
CTCXCarmell Corporation
US$ 0.6991
(150.48%)
314.15M
MBIOMustang Bio Inc
US$ 0.2093
(18.25%)
310.9M
CGBSCrown LNG Holdings Ltd
US$ 0.6749
(68.68%)
279.72M
SVMHSRIVARU Holding Ltd
US$ 0.0599
(42.28%)
278.85M

Discusión

Ver feed completo
go seek go seek 10 minutos hace
I doubt that I will ever understand why ENTA dropped 60% over the past 11 weeks.
ENTA
shoondale shoondale 14 minutos hace
Besides criminality, what experience.&.qualifications did the bribery felon possess on his resume that he was anointed president by Simon Johnston and met with praise by Jeffrey Williams? Is this their idea for "getting it right"?
https://www.law360.com/articles/1364277/attachments/0 https
MGON
THEBEASTMUGABI THEBEASTMUGABI 14 minutos hace
You always leave your comments with a question mark ? 🤔.   It disturbs me.  Please don't take that as sarcasm.  I appreciate your input.  Happy New Year.  
IONQ
nojay nojay 15 minutos hace
Looks like can check out kaspee on Kaspa. It is not on sale yet but they will be a NFT market and Kaspa trading platform when NFTs on Kaspa become active when smart contracts are integrated I think by April. But I am sure the presale will happen way before then
KASUST
BeardOfWallSt BeardOfWallSt 15 minutos hace
And upticking 
FCHS
manibiotech manibiotech 17 minutos hace
Again problem with reading comprehension
I never said I was not talking to you . Actually it was exactly opposite .
None of your tirade addresses the questions I raised 
My offer still stands . Will subsidize your tutoring 
NWBO
THEBEASTMUGABI THEBEASTMUGABI 18 minutos hace
You said what I believe, the Cream will rise to the top.  Anything quantum is going up right now. For those who are taking advantage of it, that's fantastic, but eventually it will implode in my opinion.   The one that topped out today at 30% today I believe will probably go up to 20 to $25 and that
IONQ
jeunke22 jeunke22 20 minutos hace
Just to elaborate a bit on the PR statement in December when Yves was quoted as saying:
“ … that the materials developed by the company can significantly improve the speed and energy efficiency of two critical parts of AI infrastructure the back end and front ends !”
AI Back-End Netw
LWLG
stervc stervc 25 minutos hace
shoondale, why that's not important with MGON...

There are hundreds of companies that have failed before figuring things out to become very successful. Some even turned out to be multi-billion dollar companies. All they have to do is to finally get it right once! I think they have! I
MGON
manibiotech manibiotech 27 minutos hace
I think your anger is partially misdirected
If one is not emotionally attached , the blame for killing the company or investment can be more broadly assigned 
But as I said please keep picking . If you think MMs are the only responsible party , even they like suckers . 
NWBO
rx7171 rx7171 29 minutos hace
Hopefully once the paper looked to on path for acceptance Missling started the FDA application to be ready to drop as soon as paper published.
AVXL
XMaster2023 XMaster2023 32 minutos hace
Please let us be suckers in peace. Why would A group of market makers want to kill a small biotech company trying to cure cancer? WHO would work for such a person posting nonsense 24/7/365? Your relentless posts are ridiculous. New investors will purchase NWBO because DCVax-L works
NWBO
gitreal gitreal 32 minutos hace
Nobody is denying that a mill is present in the desert north of Bishop. But driving out there and seeing it would mean diddley squat to most people, including me, and I have seen many actual operating milling operations. If you are that impressed seeing a building out in the desert, maybe you ough
NBRI
shoondale shoondale 35 minutos hace
$MGON_&_Gardiner here is the history; every product fails...Megola's Disinfectant/ Deodorizing/ Sanitizing Portable Ozone Unit Known to Kill Viruses
https://www.otcmarkets.com/stock/MGON/news/Megolas-Disinfectant-Deodorizing-Sanitizing-Portable-Ozone-Unit-Known-to-Kill-Viruses?id=279628 htt
MGON
pennystock_es pennystock_es 37 minutos hace
News THBD ?

https://x.com/PennyStock_es/status/1874908400615829687?t=tK54u__Hz1gVk3jjnmXYOw&s=19
THBD
manibiotech manibiotech 45 minutos hace
Yep they are counting on suckers who don't demand performance and accountability. Please keep picking . 
NWBO
GseHeist GseHeist 49 minutos hace
Letter basically is a response to Bill's tweet, and it basically says that FHFA needs to continue working on the exist to avoid DOGE making them a redundant agency, and they're reiterating that FHFA does not have any power (only Treasury can agree) to terminate the ConShip, and hire a high flying co
FNMA
StockItOut StockItOut 50 minutos hace
It is my theory, conclusion actually, proposed when JohnnyDope still believed in Nexboard as likely or real, and yelled at anyone stating otherwise.

My theory conclusion that JohnnyDoeseph has now adopted.

Seems a very reasonable conclusion, that Nexboard certificatio
XERI
Beauneedsbiscuits Beauneedsbiscuits 51 minutos hace
Funny you can never show proof to deny what Ive said about your multiple bad chooses. Bet you never thought your MMA promoter would be ..quintuple zeros...as most you supported are. "Freeze" company still going down and you supported that years ago..so MANY examples of your failures.
Name me
SFIO
MasterBlastr MasterBlastr 55 minutos hace
Trump 45 let the criminals take over. Biden was beating them back before Trump 47. 2017-2020 and 2025-2028 will go down in history as The Lost Years. The U.S. will lose 3-5 more years of life expectancy under 47.
AMC
Calvin Hobbes Calvin Hobbes 57 minutos hace
No you would see it on Daily list a day before anyways, NO RS coming in news.
TWOH
marcis marcis 57 minutos hace
So this is a pinned note to get excited about your “other one” you rather stay in?


~ Note; The Name-Drop of Mike Tyson & Floyd Mayweather Jr. - as Floyd showed interest
in INQD back in 2019, and Mike Tyson has his own Cannabis Company, and would
likely add an i
INQD
Calvin Hobbes Calvin Hobbes 57 minutos hace
https://x.com/oilermanhockey/status/1874893845126889525
I have my own theory. Matches yours for the most part.
TWOH
crescentmotor crescentmotor 59 minutos hace
No new long term options have shown up. Jan 16 2026 is the longest term option available.

Yes--for me that will become an issue at some point as I am likely going to want/need to move my options forward. I'm thinking/hoping price volatility over the coming months and AVXL increased
AVXL JPM

Su Consulta Reciente

NASDAQ
XOMAP
XOMA Royalty
AMEX
SKYH
Sky Harbour
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados